Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 365

1.
2.
3.

The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.

Chen CC, Wang L, Lin JC, Jan JS.

J Formos Med Assoc. 2015 Mar;114(3):231-7. doi: 10.1016/j.jfma.2012.10.021.

4.

Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.

Kim JS, Kim JS, Kim SY, Kim Ki, Cho MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53. Review.

PMID:
12654434
5.
6.

Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer.

Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, Kelley JL, Edwards RP.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):166-71.

PMID:
17321070
7.

A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.

Mabuchi S, Takahashi R, Isohashi F, Yokoi T, Ito K, Tsutui T, Ogata T, Yoshioka Y, Ogawa K, Kimura T.

Int J Gynecol Cancer. 2013 Sep;23(7):1279-86. doi: 10.1097/IGC.0b013e31829c3e32.

PMID:
23835505
8.

Feasibility of extended-field irradiation and intracavitary brachytherapy combined with weekly cisplatin chemosensitization for IB2-IIIB cervical cancer with positive paraaortic or high common iliac lymph nodes: a retrospective review.

Kuji S, Hirashima Y, Komeda S, Tanaka A, Abe M, Takahashi N, Takekuma M, Asakura H, Harada H, Nishimura T.

Int J Clin Oncol. 2014 Apr;19(2):341-7. doi: 10.1007/s10147-013-0551-8.

PMID:
23546545
9.

Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era.

Vargo JA, Kim H, Choi S, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Comerci JT, Beriwal S.

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1091-8. doi: 10.1016/j.ijrobp.2014.08.013.

PMID:
25303889
10.

Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity.

Delpech Y, Haie-Meder C, Rey A, Zafrani Y, Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P, Castaigne D, Morice P.

Ann Surg Oncol. 2007 Nov;14(11):3223-31.

PMID:
17713822
11.

Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.

Liang JA, Chen SW, Chang WC, Hung YC, Yeh LS, Yang SN, Lin FJ.

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):683-90. doi: 10.1016/j.clon.2008.06.007.

PMID:
18676129
12.

Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.

Gandhi AK, Sharma DN, Rath GK, Julka PK, Subramani V, Sharma S, Manigandan D, Laviraj MA, Kumar S, Thulkar S.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):542-8. doi: 10.1016/j.ijrobp.2013.06.2059.

PMID:
24074927
13.

Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy.

Marnitz S, Schram J, Budach V, Sackerer I, Vercellino GF, Sehouli J, Köhler C.

Strahlenther Onkol. 2015 May;191(5):421-8. doi: 10.1007/s00066-014-0785-z.

PMID:
25413986
14.

High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.

Kim YS, Kim JH, Ahn SD, Lee SW, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH, Choi EK.

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1522-8. doi: 10.1016/j.ijrobp.2008.10.024.

PMID:
19231106
15.

The role of elective para-aortic lymph node irradiation in patients with locally advanced cervical cancer.

Yap ML, Cuartero J, Yan J, Pintilie M, Fyles A, Levin W, Manchul L, Milosevic M.

Clin Oncol (R Coll Radiol). 2014 Dec;26(12):797-803. doi: 10.1016/j.clon.2014.08.008.

PMID:
25194726
16.

Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin.

Jensen LG, Hasselle MD, Rose BS, Nath SK, Hasan Y, Scanderbeg DJ, Yashar CM, Mundt AJ, Mell LK.

Int J Gynecol Cancer. 2013 Jan;23(1):119-25. doi: 10.1097/IGC.0b013e3182749114.

PMID:
23262521
17.

Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).

Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer Vulva Cancer Committee of the Japanese Gynecologic Oncology Group..

Int J Gynecol Cancer. 2012 Oct;22(8):1420-6.

PMID:
22932262
18.
19.

The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.

Yin YJ, Li HQ, Sheng XG, Du XL, Wang C, Lu CH, Pan CX.

Int J Gynecol Cancer. 2015 Jul;25(6):1058-65. doi: 10.1097/IGC.0000000000000360.

PMID:
25647254
20.

Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.

Chung YL, Jian JJ, Cheng SH, Hsieh CI, Tan TD, Chang HJ, Hung CF, Horng CF, Soong T, Tsou MH.

Gynecol Oncol. 2005 Apr;97(1):126-35.

PMID:
15790448

Supplemental Content

Support Center